Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated with Ustekinumab
Phase of Trial: Phase III
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Ustekinumab (Primary) ; Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms STARDUST
- Sponsors Janssen-Cilag
- 26 Jul 2017 Planned End Date changed from 30 Mar 2019 to 28 Jun 2019.
- 27 Apr 2017 Status changed from not yet recruiting to recruiting.
- 29 Mar 2017 New trial record